Association of serum tumor necrosis factor levels with decrease of cholesterol during septic shock.
Sir, Iain Macdougall provided, in general, a comprehensive review of once-weekly administrations of epoetin , epoetin and darbepoetin [1] . However, additional mention could have been made of the differences between epoetin and epoetin , as well as further analysis of the data from studies of subcutaneous (s.c.) administration.
With regard to the differences between epoetin and epoetin , as the article highlights, the validity of once-weekly administration has only been established in large-scale, randomized controlled trials of epoetin administration [2, 3] . Comparable data are not yet available for epoetin . The results reported by the Swedish Study Group [3] and Locatelli et al. [2] showed that once-weekly epoetin is an effective regimen in haemodialysis patients in the maintenance phase of treatment. In the Swedish study, the epoetin dose and haemoglobin level remained stable during the 24-week study, with no statistically significant differences between the groups in change from week 0 to week 24 [3] . The study reported by Locatelli et al. [2] used rigorous and validated statistical methods to show that once-weekly and three-times-weekly s.c. epoetin administrations are clinically and statistically equivalent. As Macdougall points out, the patients included in these studies were iron replete and well dialysed. However, these inclusion criteria should be regarded as standard in trials of dialysis patients; indeed, they were also adhered to in the two darbepoetin dialysis studies recently published in full [4, 5] . Furthermore, a survey conducted in 2002 of over 2000 haemodialysis patients (85% of Sweden's haemodialysis population) showed that 95% had a Kt/V of >1.0 and 92% and 80% had serum ferritin above 100 and 200 mg/l, respectively (unpublished data, Swedish Society of Nephrology); these values are also in line with current recommendations [6] . Therefore, contrary to Macdougall's remark about a highly selected, welldialysed and iron-replete population, the inclusion criteria in the epoetin trials can be considered representative of the haemodialysis population encountered in clinical practice.
The article also describes results from uncontrolled studies of once-weekly epoetin administration which indicated lack of efficacy. However, patients in the study reported by Jones et al. [7] received both epoetin and epoetin . Use of both epoetin products may have contributed to the discrepancy between these results and those reported in the epoetin b randomized trials. This hypothesis is supported by reported differences in the pharmacological properties of epoetin and epoetin [8] .
Further analysis of data from studies of s.c. administration and its advantages over the intravenous (i.v.) route could also have been provided. For example, with regard to the evaluation of pharmacokinetic profiles, the article only compares the half-lives of i.v. darbepoetin and i.v. epoetin (25.3 and 8.5 h, respectively). A comparison should also be made with s.c. epoetin; the reported half-lives of s.c. epoetin and s.c. epoetin are 19.4 and 24.2 h, respectively [8] . In addition, s.c. administration gives patients the option to self-administer erythropoietic treatment, and s.c. epoetin has been shown to be more cost-effective than i.v. epoetin [9] . Moreover, in comparison with the i.v. route, s.c. administration may be associated with reduced incidences of erythropoietin-associated hypertension [10] . These benefits, as well as the differences in epoetin and epoetin clinical profiles, should be taken into account in an evaluation of erythropoietic therapy. Reply Sir, I would like to thank Lars Weiss for his interesting comments regarding my Editorial Comment [1] from over a year ago! However, I do have some difficulty accepting one or two of his arguments. While one cannot completely exclude the possibility of different pharmacodynamics between epoetin alfa and epoetin beta, I feel it is unlikely that a difference in intravenous (i.v.) half-life of 6.8±2.7 h for i.v. epoetin alfa and 8.8±2.2 h for i.v. epoetin beta, along with 19.4±10.7 h for subcutaneous (s.c.) epoetin alfa and 24.2±11.2 h for s.c. epoetin beta [2] can really make a substantial difference to biological activity. There may be other differences between epoetin alfa and epoetin beta previously unrecognized, but it would be surprising if such subtle differences in pharmacokinetics in a study conducted in healthy volunteers translated into an enhanced clinical efficacy. However, I do accept completely Weiss's comment that inclusion criteria including only iron-replete and welldialysed patients should be 'regarded as standard in trials of dialysis patients'. As I said in my Editorial Comment [1] , and in a follow-up Reply Letter [3] , it is always difficult to extrapolate results from scientific studies into everyday clinical practice. While one cannot criticize the inclusion criteria in either the Swedish [4] or Italian [5] studies, the experience of Jones et al. [6] and Geddes and Woo [7] testify to this. I also disagree with Weiss's comment that a Kt/V of >1 and a ferritin level of >200 mg/l are the 'norm' in dialysis units; I accept the unpublished data from the Swedish Society of Nephrology, but it is well known that Sweden boasts some of the best results in renal anaemia management in Europe (as reported in the ESAM survey [8] ), and the experience in other countries in Europe falls far short of the results that Weiss quotes. Thus, I still feel that we should be cautious about extrapolating results from wellcontrolled clinical trials into everyday clinical practice in our dialysis units.
Finally, although half-lives aren't everything, before getting too excited about a possible difference between 19.4 and 24.2 h for s.c. administration of epoetin alfa and epoetin beta, respectively, one should not forget that the half-life for s.c. darbepoetin alfa is substantially greater at 48.8±12.7 h [9] . 
